Literature DB >> 30002489

Integrating endocannabinoid signaling in the regulation of anxiety and depression.

An-Qi Yin1, Feng Wang2, Xia Zhang1,3.   

Abstract

Brain endogenous cannabinoid (eCB) signaling seems to harmonize appropriate behavioral responses, which are essential for the organism's long-term viability and homeostasis. Dysregulation of eCB signaling contributes to negative emotional states and increased stress responses. An understanding of the underlying neural cell populations and neural circuit regulation will enable the development of therapeutic strategies to mitigate behavioral maladaptation and provide insight into the influence of eCB on the neural circuits involved in anxiety and depression. This review focuses on recent evidence that has added a new layer of complexity to the idea of targeting the eCB system for therapeutic benefits in neuropsychiatric disease and on the future research direction of neural circuit modulation.

Entities:  

Keywords:  anxiety; cannabinoid 1 receptor (CB1R); depression; endocannabinoid (eCB); neural circuits

Mesh:

Substances:

Year:  2018        PMID: 30002489      PMCID: PMC6460364          DOI: 10.1038/s41401-018-0051-5

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  76 in total

1.  Cannabis based drug is licensed for spasticity in patients with MS.

Authors:  Zosia Kmietowicz
Journal:  BMJ       Date:  2010-06-22

2.  Endocannabinoids drive the acquisition of an alternative phenotype in microglia.

Authors:  M Mecha; A Feliú; F J Carrillo-Salinas; A Rueda-Zubiaurre; S Ortega-Gutiérrez; R García de Sola; C Guaza
Journal:  Brain Behav Immun       Date:  2015-06-15       Impact factor: 7.217

3.  Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD.

Authors:  Jing Han; Philip Kesner; Mathilde Metna-Laurent; Tingting Duan; Lin Xu; Francois Georges; Muriel Koehl; Djoher Nora Abrous; Juan Mendizabal-Zubiaga; Pedro Grandes; Qingsong Liu; Guang Bai; Wei Wang; Lize Xiong; Wei Ren; Giovanni Marsicano; Xia Zhang
Journal:  Cell       Date:  2012-03-02       Impact factor: 41.582

Review 4.  A critical role for prefrontocortical endocannabinoid signaling in the regulation of stress and emotional behavior.

Authors:  Ryan J McLaughlin; Matthew N Hill; Boris B Gorzalka
Journal:  Neurosci Biobehav Rev       Date:  2014-02-26       Impact factor: 8.989

5.  Marijuana intoxication common experiences.

Authors:  C T Tart
Journal:  Nature       Date:  1970-05-23       Impact factor: 49.962

Review 6.  Pathophysiology related to peripheral vascular disease.

Authors:  M M Wagner
Journal:  Nurs Clin North Am       Date:  1986-06       Impact factor: 1.208

Review 7.  Amygdala FAAH and anandamide: mediating protection and recovery from stress.

Authors:  Ozge Gunduz-Cinar; Matthew N Hill; Bruce S McEwen; Andrew Holmes
Journal:  Trends Pharmacol Sci       Date:  2013-10-25       Impact factor: 14.819

Review 8.  Don't Worry, Be Happy: Endocannabinoids and Cannabis at the Intersection of Stress and Reward.

Authors:  Nora D Volkow; Aidan J Hampson; Ruben D Baler
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016-09-02       Impact factor: 13.820

Review 9.  Multiple functions of endocannabinoid signaling in the brain.

Authors:  István Katona; Tamás F Freund
Journal:  Annu Rev Neurosci       Date:  2012-04-17       Impact factor: 12.449

Review 10.  The endocannabinoid system in guarding against fear, anxiety and stress.

Authors:  Beat Lutz; Giovanni Marsicano; Rafael Maldonado; Cecilia J Hillard
Journal:  Nat Rev Neurosci       Date:  2015-12       Impact factor: 34.870

View more
  9 in total

1.  Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice.

Authors:  Amaya Austrich-Olivares; María Salud García-Gutiérrez; Lucía Illescas; Ani Gasparyan; Jorge Manzanares
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-13

2.  Higher Risk of Anxiety and Depression in Women with Adenomyosis as Compared with Those with Uterine Leiomyoma.

Authors:  Ni Li; Ming Yuan; Qiuju Li; Miaomiao Ji; Xue Jiao; Guoyun Wang
Journal:  J Clin Med       Date:  2022-05-07       Impact factor: 4.964

Review 3.  Meet Your Stress Management Professionals: The Endocannabinoids.

Authors:  Terri A deRoon-Cassini; Todd M Stollenwerk; Margaret Beatka; Cecilia J Hillard
Journal:  Trends Mol Med       Date:  2020-08-28       Impact factor: 11.951

4.  Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow.

Authors:  Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2019-01-22       Impact factor: 7.169

Review 5.  Cannabinoid Control of Olfactory Processes: The Where Matters.

Authors:  Geoffrey Terral; Giovanni Marsicano; Pedro Grandes; Edgar Soria-Gómez
Journal:  Genes (Basel)       Date:  2020-04-16       Impact factor: 4.096

Review 6.  From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?

Authors:  Rafael M Bitencourt; Reinaldo N Takahashi; Elisaldo A Carlini
Journal:  Front Psychiatry       Date:  2021-02-11       Impact factor: 4.157

7.  Inducible Nitric Oxide Synthase Inhibition in the Medial Prefrontal Cortex Attenuates the Anxiogenic-Like Effect of Acute Restraint Stress via CB1 Receptors.

Authors:  Arthur A Coelho; Carla Vila-Verde; Ariandra G Sartim; Daniela L Uliana; Laura A Braga; Francisco S Guimarães; Sabrina F Lisboa
Journal:  Front Psychiatry       Date:  2022-07-14       Impact factor: 5.435

8.  Electroacupuncture Reduces Anxiety Associated With Inflammatory Bowel Disease By Acting on Cannabinoid CB1 Receptors in the Ventral Hippocampus in Mice.

Authors:  Xue-Fei Hu; Hong Zhang; Ling-Ling Yu; Wen-Qiang Ge; Ou-Yang Zhan-Mu; Yan-Zhen Li; Chao Chen; Teng-Fei Hou; Hong-Chun Xiang; Yuan-Heng Li; Yang-Shuai Su; Xiang-Hong Jing; Jie Cao; Hui-Lin Pan; Wei He; Man Li
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

Review 9.  Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors.

Authors:  Si-Yu Ren; Zhen-Zhen Wang; Yi Zhang; Nai-Hong Chen
Journal:  Acta Pharmacol Sin       Date:  2020-03-18       Impact factor: 6.150

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.